文献速递肺栓塞与肺血管病呼吸道感染呼吸危重症与机械通气

COVID-19、免疫血栓形成与静脉血栓栓塞症的生物学机制

COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms.
PubMed 文献 · Thorax · 2021-01-06

本文为叙述性综述,聚焦COVID-19相关凝血病、病理、内皮功能障碍与止血、免疫系统与血栓、遗传关联及其他血栓机制。COVID-19中血栓事件以静脉血栓栓塞症(VTE)为主,与疾病严重度和不良临床结局相关。促炎环境可导致免疫血栓形成失调,形成主要累及微血管的免疫介导血栓。

要点

  • COVID-19血栓事件以VTE为主,与疾病严重度和不良结局相关。
  • COVID-19相关凝血病伴细胞因子升高及血小板、内皮和补体激活。
  • 免疫血栓形成失调主要累及微血管,涉及止血与免疫系统复杂交互。

核心结论

  • COVID-19中促炎环境可导致免疫血栓形成失调,形成主要累及微血管的免疫介导血栓。
  • 止血与免疫系统 intricately linked,多因素过程共同参与COVID-19的VTE和免疫血栓形成。

研究设计与样本

  • 本文为state-of-the-art叙述性综述,探讨COVID-19中免疫血栓形成与VTE的病理生物学机制。

主要发现

  • COVID-19中频繁发生的血栓事件以静脉血栓栓塞症(VTE)为主,与疾病严重度增加和更差临床结局相关。
  • COVID-19 distinctive微血管异常包括内皮炎症、细胞间连接破坏和微血栓形成。
  • COVID-19相关凝血病伴细胞因子升高及血小板、内皮和补体激活,随疾病严重度增加更常见。

临床怎么用

  • 理解免疫血栓形成与VTE的复杂交互,有助于开发和评估新治疗对COVID-19血栓事件的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Thrombotic events that frequently occur in COVID-19 are predominantly venous thromboemboli (VTE) and are associated with increasing disease severity and worse clinical outcomes. Distinctive microvascular abnormalities in COVID-19 include endothelial inflammation, disruption of intercellular junctions and microthrombi formation. A distinct COVID-19-associated coagulopathy along with increased cytokines and activation of platelets, endothelium and complement occur in COVID-19, which is more frequent with worsening disease severity. This proinflammatory milieu may result in immunothrombosis, a host defence mechanism that can become dysregulated, leading to excess formation of immunologically mediated thrombi which predominantly affect the microvasculature. The haemostatic and immune systems are intricately linked, and multifactorial processes are likely to contribute to VTE and immunothrombosis in COVID-19. This state-of-the-art review will explore the pathobiological mechanisms of immunothrombosis and VTE in COVID-19 focusing on: COVID-19-associated coagulopathy, pathology, endothelial dysfunction and haemostasis, the immune system and thrombosis, genetic associations and additional thrombotic mechanisms. An understanding of the complex interplay between these processes is necessary for developing and assessing how new treatments affect VTE and immunothrombosis in COVID-19.

来源:Thorax,查看原文。版权归原作者所有。

引用

  1. Loo J, Spittle DA, Newnham M, et al. COVID-19, immunothrombosis and venous thromboembolism: biological mechanisms. Thorax. 2021. PMID: 33408195. doi:10.1136/thoraxjnl-2020-216243

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。